-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, April 20, reported that the fifth batch of centralized procurement report volume catalog is very authentic.
It is reported that the report volume has been started.
According to the work rhythm, the volume report will start in April.
It is expected that the catalog will be confirmed and the formal purchase will be issued in May.
Announcement, bid opening in June.
It is reported that the report volume has been started.
According to the work rhythm, the volume report will start in April.
It is expected that the catalog will be confirmed and the formal purchase will be issued in May.
Announcement, bid opening in June.
Of course, the information is subject to the official announcement! This article is for reference and thinking only.
The importance of reporting is self-evident
Regarding the importance of reporting, we collected the "four chains" in the previous article: Quotation-Quotation-Market Selection-Offensive and Defensive after the bidding, overall consideration, and analysis for you in the unified planning.
The reporting is based on the centralized procurement system.
From the policy to the first starting point after implementation, it not only affects the later selection and use of hospitals , but also affects whether it can honor the policy of surplus retention.
The reporting is based on the centralized procurement system.
From the policy to the first starting point after implementation, it not only affects the later selection and use of hospitals , but also affects whether it can honor the policy of surplus retention.
Of course, many companies are also taking active actions.
Hasn't the catalogue been officially announced yet? Isn’t there still room for consolidation, adjustment, and improvement? Isn't everything the result of consensus reached by all parties?
Hasn't the catalogue been officially announced yet? Isn’t there still room for consolidation, adjustment, and improvement? Isn't everything the result of consensus reached by all parties?
The fifth batch of Chinese patent medicines and biosimilars not included
The online reporting volume catalogue has 60 varieties and 207 grades, which is the largest number of varieties included since the 4+7 collection in 2018, and there are 30 injections, which has truly entered the era of injections and the centralized collection of heavy varieties.
era.
era.
However, this time it has not yet involved proprietary Chinese medicines and biological products that are of great concern to the industry.
These two types of medicines are less standardized than chemical medicines.
How to classify (split or merge) and treat them according to their indications/functions? Or consider some varieties that have the attributes of drugs + consumables + services? This is one of the difficulties of centralized procurement.
These two types of medicines are less standardized than chemical medicines.
How to classify (split or merge) and treat them according to their indications/functions? Or consider some varieties that have the attributes of drugs + consumables + services? This is one of the difficulties of centralized procurement.
In addition, for biosimilar drugs, the first domestic species has only appeared since 2019, although so far, adalimumab, bevacizumab, and rituximab have all reached or exceeded three, satisfying the needs of centralized procurement.
"Trigger mechanism", but several players in this field, such as Qilu, Fuhong Henlius, Hisun, Cinda, and Biotech are not easy to start businesses and commercialization is not easy.
Should we consider choosing a more secure way to advance?
"Trigger mechanism", but several players in this field, such as Qilu, Fuhong Henlius, Hisun, Cinda, and Biotech are not easy to start businesses and commercialization is not easy.
Should we consider choosing a more secure way to advance?
What is the trigger mechanism of centralized procurement?
According to the State Council’s [2021] No.
2 document and the statement of the relevant person in charge of the National Medical Insurance Administration, there is no restricted area for centralized procurement of proprietary Chinese medicines and biosimilar drugs, and “there is no doubt that they will be included in the centralized procurement”.
Generic drugs that have passed the consistency evaluation can be included in centralized procurement as long as they reach three.
" "
2 document and the statement of the relevant person in charge of the National Medical Insurance Administration, there is no restricted area for centralized procurement of proprietary Chinese medicines and biosimilar drugs, and “there is no doubt that they will be included in the centralized procurement”.
Generic drugs that have passed the consistency evaluation can be included in centralized procurement as long as they reach three.
" "
As of April 14, 2021, the medical cloud studio has counted 82 varieties that meet the requirements of "original research + over-evaluation of three or more".
However, the report volume catalogue shows 60 varieties, so why are the remaining 22 varieties not included in the collection? Among them, there are many PPIs with mature clinical use and large purchase amount.
However, the report volume catalogue shows 60 varieties, so why are the remaining 22 varieties not included in the collection? Among them, there are many PPIs with mature clinical use and large purchase amount.
Obviously, we believe that the so-called "trigger mechanism" still needs to be specifically evaluated in specific varieties, and factors such as product particularity, capacity, quality risk, medication risk, and use mode have to be fully considered.
Recently, Banner.
com published a signed article "Building a New Pattern of Medical Price Governance" by the responsible comrades of the National Medical Insurance Bureau, which puts forward a very constructive and creative idea for the next step of centralized procurement work, which is worthy of the industry's good taste.
com published a signed article "Building a New Pattern of Medical Price Governance" by the responsible comrades of the National Medical Insurance Bureau, which puts forward a very constructive and creative idea for the next step of centralized procurement work, which is worthy of the industry's good taste.
The article pointed out that it is necessary to continuously improve and develop centralized procurement with a comprehensive use of procurement volume, contract period, competition, and substitution, and constantly innovate the centralized procurement toolbox.
Centralized procurement of varieties with strong universality in accordance with uniform rules
Promote high-value medical consumables according to "one product, one policy"
Exploring special centralized procurement for more characteristic varieties
Explore, merge, and centrally purchase varieties with similar indications and functions and indications
Explore the large changes in the supply and demand relationship and purchase by staged bargaining
It can be seen from the above-mentioned ideas that the fifth batch of collectively-collected varieties still belong to the “universal varieties”, so they are collected in accordance with the rules that have gradually matured from the third batch.
Since the first batch of high-value consumables, although there is only one variety-the centralized procurement of coronary stents, the pattern is very broad and the rule-making is very skillful.
It not only respects the types and purchases of medical institutions, but also provides The open access door was fully competitive, so a historic price cut was achieved.
Following this line of thinking, the second batch of bone and joint consumables will also be “one product, one policy”.
It not only respects the types and purchases of medical institutions, but also provides The open access door was fully competitive, so a historic price cut was achieved.
Following this line of thinking, the second batch of bone and joint consumables will also be “one product, one policy”.
For varieties with strong characteristics, varieties with similar indications or functional indications, and varieties with greater changes in the supply and demand relationship, different methods of "exploration" based on product characteristics may be used at the national and local levels.
Medical Network, April 20, reported that the fifth batch of centralized procurement report volume catalog is very authentic.
It is reported that the report volume has been started.
According to the work rhythm, the volume report will start in April.
It is expected that the catalog will be confirmed and the formal purchase will be issued in May.
Announcement, bid opening in June.
It is reported that the report volume has been started.
According to the work rhythm, the volume report will start in April.
It is expected that the catalog will be confirmed and the formal purchase will be issued in May.
Announcement, bid opening in June.
Of course, the information is subject to the official announcement! This article is for reference and thinking only.
The importance of reporting is self-evident
Regarding the importance of reporting, we collected the "four chains" in the previous article: Quotation-Quotation-Market Selection-Offensive and Defensive after the bidding, overall consideration, and analysis for you in the unified planning.
The reporting is based on the centralized procurement system.
From the policy to the first starting point after implementation, it not only affects the later selection and use of hospitals , but also affects whether it can honor the policy of surplus retention.
The reporting is based on the centralized procurement system.
From the policy to the first starting point after implementation, it not only affects the later selection and use of hospitals , but also affects whether it can honor the policy of surplus retention.
Of course, many companies are also taking active actions.
Hasn't the catalogue been officially announced yet? Isn’t there still room for consolidation, adjustment, and improvement? Isn't everything the result of consensus reached by all parties?
Hasn't the catalogue been officially announced yet? Isn’t there still room for consolidation, adjustment, and improvement? Isn't everything the result of consensus reached by all parties?
The fifth batch of Chinese patent medicines and biosimilars not included
The online reporting volume catalogue has 60 varieties and 207 grades, which is the largest number of varieties included since the 4+7 collection in 2018, and there are 30 injections, which has truly entered the era of injections and the centralized collection of heavy varieties.
era.
era.
However, this time it has not yet involved proprietary Chinese medicines and biological products that are of great concern to the industry.
These two types of medicines are less standardized than chemical medicines.
How to classify (split or merge) and treat them according to their indications/functions? Or consider some varieties that have the attributes of drugs + consumables + services? This is one of the difficulties of centralized procurement.
These two types of medicines are less standardized than chemical medicines.
How to classify (split or merge) and treat them according to their indications/functions? Or consider some varieties that have the attributes of drugs + consumables + services? This is one of the difficulties of centralized procurement.
In addition, for biosimilar drugs, the first domestic species has only appeared since 2019, although so far, adalimumab, bevacizumab, and rituximab have all reached or exceeded three, satisfying the needs of centralized procurement.
"Trigger mechanism", but several players in this field, such as Qilu, Fuhong Henlius, Hisun, Cinda, and Biotech are not easy to start businesses and commercialization is not easy.
Should we consider choosing a more secure way to advance?
"Trigger mechanism", but several players in this field, such as Qilu, Fuhong Henlius, Hisun, Cinda, and Biotech are not easy to start businesses and commercialization is not easy.
Should we consider choosing a more secure way to advance?
What is the trigger mechanism of centralized procurement?
According to the State Council’s [2021] No.
2 document and the statement of the relevant person in charge of the National Medical Insurance Administration, there is no restricted area for centralized procurement of proprietary Chinese medicines and biosimilar drugs, and “there is no doubt that they will be included in the centralized procurement”.
Generic drugs that have passed the consistency evaluation can be included in centralized procurement as long as they reach three.
" "
2 document and the statement of the relevant person in charge of the National Medical Insurance Administration, there is no restricted area for centralized procurement of proprietary Chinese medicines and biosimilar drugs, and “there is no doubt that they will be included in the centralized procurement”.
Generic drugs that have passed the consistency evaluation can be included in centralized procurement as long as they reach three.
" "
As of April 14, 2021, the medical cloud studio has counted 82 varieties that meet the requirements of "original research + over-evaluation of three or more".
However, the report volume catalogue shows 60 varieties, so why are the remaining 22 varieties not included in the collection? Among them, there are many PPIs with mature clinical use and large purchase amount.
However, the report volume catalogue shows 60 varieties, so why are the remaining 22 varieties not included in the collection? Among them, there are many PPIs with mature clinical use and large purchase amount.
Obviously, we believe that the so-called "trigger mechanism" still needs to be specifically evaluated in specific varieties, and factors such as product particularity, capacity, quality risk, medication risk, and use mode have to be fully considered.
Recently, Banner.
com published a signed article "Building a New Pattern of Medical Price Governance" by the responsible comrades of the National Medical Insurance Bureau, which puts forward a very constructive and creative idea for the next step of centralized procurement work, which is worthy of the industry's good taste.
com published a signed article "Building a New Pattern of Medical Price Governance" by the responsible comrades of the National Medical Insurance Bureau, which puts forward a very constructive and creative idea for the next step of centralized procurement work, which is worthy of the industry's good taste.
The article pointed out that it is necessary to continuously improve and develop centralized procurement with a comprehensive use of procurement volume, contract period, competition, and substitution, and constantly innovate the centralized procurement toolbox.
Centralized procurement of varieties with strong universality in accordance with uniform rules
Promote high-value medical consumables according to "one product, one policy"
Exploring special centralized procurement for more characteristic varieties
Explore, merge, and centrally purchase varieties with similar indications and functions and indications
Explore the large changes in the supply and demand relationship and purchase by staged bargaining
It can be seen from the above-mentioned ideas that the fifth batch of collectively-collected varieties still belong to the “universal varieties”, so they are collected in accordance with the rules that have gradually matured from the third batch.
Since the first batch of high-value consumables, although there is only one variety-the centralized procurement of coronary stents, the pattern is very broad and the rule-making is very skillful.
It not only respects the types and purchases of medical institutions, but also provides The open access door was fully competitive, so a historic price cut was achieved.
Following this line of thinking, the second batch of bone and joint consumables will also be “one product, one policy”.
It not only respects the types and purchases of medical institutions, but also provides The open access door was fully competitive, so a historic price cut was achieved.
Following this line of thinking, the second batch of bone and joint consumables will also be “one product, one policy”.
For varieties with strong characteristics, varieties with similar indications or functional indications, and varieties with greater changes in the supply and demand relationship, different methods of "exploration" based on product characteristics may be used at the national and local levels.
Medical Network, April 20, reported that the fifth batch of centralized procurement report volume catalog is very authentic.
It is reported that the report volume has been started.
According to the work rhythm, the volume report will start in April.
It is expected that the catalog will be confirmed and the formal purchase will be issued in May.
Announcement, bid opening in June.
It is reported that the report volume has been started.
According to the work rhythm, the volume report will start in April.
It is expected that the catalog will be confirmed and the formal purchase will be issued in May.
Announcement, bid opening in June.
Of course, the information is subject to the official announcement! This article is for reference and thinking only.
The importance of reporting is self-evident
The importance of reporting is self-evident Regarding the importance of reporting, we collected the "four chains" in the previous article: Quotation-Quotation-Market Selection-Offensive and Defensive after the bidding, overall consideration, and analysis for you in the unified planning.
The reporting is based on the centralized procurement system.
From the policy to the first starting point after implementation, it not only affects the later selection and use of hospitals , but also affects whether it can honor the policy of surplus retention.
Hospital hospital hospitalThe reporting is based on the centralized procurement system.
From the policy to the first starting point after implementation, it not only affects the later selection and use of hospitals , but also affects whether it can honor the policy of surplus retention.
Of course, many companies are also taking active actions.
Hasn't the catalogue been officially announced yet? Isn’t there still room for consolidation, adjustment, and improvement? Isn't everything the result of consensus reached by all parties?
Enterprise business enterpriseHasn't the catalogue been officially announced yet? Isn’t there still room for consolidation, adjustment, and improvement? Isn't everything the result of consensus reached by all parties?
The fifth batch of Chinese patent medicines and biosimilars not included
The fifth batch of Chinese patent medicines and biosimilars not included The online reporting volume catalogue has 60 varieties and 207 grades, which is the largest number of varieties included since the 4+7 collection in 2018, and there are 30 injections, which has truly entered the era of injections and the centralized collection of heavy varieties.
era.
era.
However, this time it has not yet involved proprietary Chinese medicines and biological products that are of great concern to the industry.
These two types of medicines are less standardized than chemical medicines.
How to classify (split or merge) and treat them according to their indications/functions? Or consider some varieties that have the attributes of drugs + consumables + services? This is one of the difficulties of centralized procurement.
Medicine, medicine, medicineThese two types of medicines are less standardized than chemical medicines.
How to classify (split or merge) and treat them according to their indications/functions? Or consider some varieties that have the attributes of drugs + consumables + services? This is one of the difficulties of centralized procurement.
In addition, for biosimilar drugs, the first domestic species has only appeared since 2019, although so far, adalimumab, bevacizumab, and rituximab have all reached or exceeded three, satisfying the needs of centralized procurement.
"Trigger mechanism", but several players in this field, such as Qilu, Fuhong Henlius, Hisun, Cinda, and Biotech are not easy to start businesses and commercialization is not easy.
Should we consider choosing a more secure way to advance?
Venture Venture Venture"Trigger mechanism", but several players in this field, such as Qilu, Fuhong Henlius, Hisun, Cinda, and Biotech are not easy to start businesses and commercialization is not easy.
Should we consider choosing a more secure way to advance?
What is the trigger mechanism of centralized procurement?
What is the trigger mechanism of centralized procurement? According to the State Council’s [2021] No.
2 document and the statement of the relevant person in charge of the National Medical Insurance Administration, there is no restricted area for centralized procurement of proprietary Chinese medicines and biosimilar drugs, and “there is no doubt that they will be included in the centralized procurement”.
Generic drugs that have passed the consistency evaluation can be included in centralized procurement as long as they reach three.
" "
2 document and the statement of the relevant person in charge of the National Medical Insurance Administration, there is no restricted area for centralized procurement of proprietary Chinese medicines and biosimilar drugs, and “there is no doubt that they will be included in the centralized procurement”.
Generic drugs that have passed the consistency evaluation can be included in centralized procurement as long as they reach three.
" "
As of April 14, 2021, the medical cloud studio has counted 82 varieties that meet the requirements of "original research + over-evaluation of three or more".
However, the report volume catalogue shows 60 varieties, so why are the remaining 22 varieties not included in the collection? Among them, there are many PPIs with mature clinical use and large purchase amount.
Medicine Medicine MedicineHowever, the report volume catalogue shows 60 varieties, so why are the remaining 22 varieties not included in the collection? Among them, there are many PPIs with mature clinical use and large purchase amount.
Obviously, we believe that the so-called "trigger mechanism" still needs to be specifically evaluated in specific varieties, and factors such as product particularity, capacity, quality risk, medication risk, and use mode have to be fully considered.
Recently, Banner.
com published a signed article "Building a New Pattern of Medical Price Governance" by the responsible comrades of the National Medical Insurance Bureau, which puts forward a very constructive and creative idea for the next step of centralized procurement work, which is worthy of the industry's good taste.
com published a signed article "Building a New Pattern of Medical Price Governance" by the responsible comrades of the National Medical Insurance Bureau, which puts forward a very constructive and creative idea for the next step of centralized procurement work, which is worthy of the industry's good taste.
The article pointed out that it is necessary to continuously improve and develop centralized procurement with a comprehensive use of procurement volume, contract period, competition, and substitution, and constantly innovate the centralized procurement toolbox.
Centralized procurement of varieties with strong universality in accordance with uniform rules
Centralized procurement of varieties with strong universality in accordance with uniform rules Promote high-value medical consumables according to "one product, one policy"
Promote high-value medical consumables according to "one product, one policy" Exploring special centralized procurement for more characteristic varieties
Exploring special centralized procurement for more characteristic varieties Explore, merge, and centrally purchase varieties with similar indications and functions and indications
Explore, merge, and centrally purchase varieties with similar indications and functions and indications Explore the large changes in the supply and demand relationship and purchase by staged bargaining
Explore the large changes in the supply and demand relationship and purchase by staged bargaining It can be seen from the above-mentioned ideas that the fifth batch of collectively-collected varieties still belong to the “universal varieties”, so they are collected in accordance with the rules that have gradually matured from the third batch.
Since the first batch of high-value consumables, although there is only one variety-the centralized procurement of coronary stents, the pattern is very broad and the rule-making is very skillful.
It not only respects the types and purchases of medical institutions, but also provides The open access door was fully competitive, so a historic price cut was achieved.
Following this line of thinking, the second batch of bone and joint consumables will also be “one product, one policy”.
It not only respects the types and purchases of medical institutions, but also provides The open access door was fully competitive, so a historic price cut was achieved.
Following this line of thinking, the second batch of bone and joint consumables will also be “one product, one policy”.
For varieties with strong characteristics, varieties with similar indications or functional indications, and varieties with greater changes in the supply and demand relationship, different methods of "exploration" based on product characteristics may be used at the national and local levels.
